Loading
Life sciences · Phase 1/2 Trial
ClinicalTrials.gov · October 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1/2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05358249). This is a study registration, not published results. Lead sponsor: Novartis Pharmaceuticals. Recruitment status: TERMINATED. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 74 participants (ACTUAL). Conditions: KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Colorectal Cancer, Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumors, Neoplasms, Colorectal. Interventions: DRUG: JDQ443; DRUG: trametinib; DRUG: Ribociclib; BIOLOGICAL: cetuximab. Primary outcome measures: Dose escalation: Incidence and severity of dose limiting toxicities (DLTs) of each combination treatment. , 28 days; Dose escalation: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) by treatment , 24 months; Dose escalation: Frequency of dose interruptions and reductions, by treatment , 24 months; Dose Escalation: Dose intensity by treatment , 24 months; PhaseII: Overall Response Rate by Blinded Independent Review Committee (BIRC) per RECIST 1.1 , 24 months. Brief summary: This was Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.